Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $2.9 million.

  • Corvus Pharmaceuticals' Cash & Equivalents fell 38.74% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 38.74%. This contributed to the annual value of $8.7 million for FY2024, which is 30.74% down from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Cash & Equivalents stood at $2.9 million, which was down 80.48% from $14.7 million recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Cash & Equivalents ranged from a high of $31.5 million in Q1 2022 and a low of $2.9 million during Q3 2025.
  • Over the past 3 years, Corvus Pharmaceuticals' median Cash & Equivalents value was $8.7 million (recorded in 2024), while the average stood at $9.8 million.
  • Within the past 5 years, the most significant YoY rise in Corvus Pharmaceuticals' Cash & Equivalents was 93.80% (2024), while the steepest drop was 76.72% (2024).
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Cash & Equivalents stood at $13.2 million in 2022, then fell by 4.10% to $12.6 million in 2023, then plummeted by 30.74% to $8.7 million in 2024, then plummeted by 38.74% to $2.9 million in 2025.
  • Its Cash & Equivalents stands at $2.9 million for Q3 2025, versus $14.7 million for Q2 2025 and $5.0 million for Q1 2025.